ArticleBiochemistry and biophysics reports2025
Anti-inflammatory effect of lamivudine on ulcerative colitis.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a non-specific inflammatory bowel disease characterized by ulcers and erosions in the colonic mucosa, leading to a chronic cycle with alternating periods of remission and exacerbation. Ascribed to its elusive etiology, primary therapy is limited to symptomatic treatment. Consequently, there is a pressing need to identify novel therapeutic agents for UC. Lamivudine, a nucleoside analog known for its antiviral properties and Long Interspersed Nuclear Element 1 (LINE-1) inhibitory effects, was investigated for its potential anti-inflammatory role in UC. Thus, this study aimed to investigate the anti-inflammatory effect of lamivudine on DSS (Dextran Sulphate Sodium)-induced ulcerative colitis (UC) in mice. Briefly, the mice were randomly assigned to the control group, the model group, or the lamivudine group. Following the administration of the predefined treatments, the mice were monitored, and the disease activity index (DAI) score was calculated. Moreover, histological analysis was performed to examine the efficacy of lamivudine in alleviating colitis-induced damage to the large intestine. Additionally, hematoxylin-eosin (HE) staining was performed to detect pathological alterations in intestinal tissues. Finally, the levels of IL-6, IL-17, IL-10, and TNF-α were measured using enzyme-linked immunosorbent assay (ELISA). The results revealed that the DAI score and enteritis pathological score were significantly lower in the lamivudine group compared to the model group (P < 0.05). Additionally, lamivudine significantly down-regulated the expression of the inflammatory factors IL-6, IL-17, and TNF-α in intestinal tissues and concomitantly up-regulated the expression of the anti-inflammatory factor IL-10. Lastly, lamivudine significantly attenuated the symptoms of colitis and the level of intestinal inflammation in mice and exerted anti-inflammatory effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.